GDRX Stock Forecast 2025-2026
Distance to GDRX Price Targets
GDRX Price Momentum
10 Quality Stocks Worth Considering Now
Researching GoodRx (GDRX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on GDRX and similar high-potential opportunities.
Latest GDRX Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, GDRX has a neutral consensus with a median price target of $6.00 (ranging from $4.75 to $9.00). The overall analyst rating is Buy (7.8/10). Currently trading at $4.80, the median forecast implies a 25.0% upside. This outlook is supported by 8 Buy, 7 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Scott Schoenhaus at Keybanc, projecting a 87.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GDRX Analyst Ratings
GDRX Price Target Range
Latest GDRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GDRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2025 | Truist Securities | Jailendra Singh | Hold | Maintains | $5.50 |
| Feb 28, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $8.00 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $6.25 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $6.00 |
| Dec 17, 2024 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $6.00 |
| Nov 13, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $7.00 |
| Nov 11, 2024 | Barclays | Stephanie Davis | Overweight | Maintains | $6.00 |
| Aug 16, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $10.00 |
| Aug 9, 2024 | UBS | Kevin Caliendo | Neutral | Maintains | $8.50 |
| Aug 9, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $10.00 |
| Jun 10, 2024 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $9.50 |
| May 23, 2024 | RBC Capital | Mark Mahaney | Outperform | Upgrade | $10.00 |
| May 20, 2024 | Barclays | Stephanie Davis | Overweight | Maintains | $10.00 |
| May 16, 2024 | TD Cowen | Charles Rhyee | Buy | Maintains | $16.00 |
| May 16, 2024 | Raymond James | John Ransom | Outperform | Upgrade | $10.00 |
| Apr 10, 2024 | Keybanc | Scott Schoenhaus | Overweight | Upgrade | $9.00 |
| Mar 25, 2024 | Wells Fargo | Stan Berenshteyn | Overweight | Upgrade | $10.00 |
| Mar 8, 2024 | RBC Capital | Sean Dodge | Sector Perform | Reiterates | $8.00 |
| Mar 1, 2024 | UBS | Eric Sheridan | Neutral | Maintains | $8.00 |
| Mar 1, 2024 | Truist Securities | Jailendra Singh | Hold | Maintains | $8.00 |
GoodRx Holdings Inc. (GDRX) Competitors
The following stocks are similar to GoodRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GoodRx Holdings Inc. (GDRX) Financial Data
GoodRx Holdings Inc. has a market capitalization of $1.77B with a P/E ratio of 115.3x. The company generates $792.32M in trailing twelve-month revenue with a 2.1% profit margin.
Revenue growth is +1.0% quarter-over-quarter, while maintaining an operating margin of +19.4% and return on equity of +2.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
GoodRx Holdings Inc. (GDRX) Business Model
About GoodRx Holdings Inc.
Provides affordable prescription drug solutions.
The company operates a digital healthcare platform that aggregates pricing data from over 70,000 pharmacies, enabling users to find discounts, coupons, and compare medication prices. GoodRx generates revenue primarily through advertising and referral fees from pharmacies when users redeem prescriptions via its platform.
GoodRx addresses the critical issue of high medication costs in the U.S., catering especially to uninsured individuals or those struggling with prescription prices. The company is headquartered in Santa Monica, California, and utilizes technology to enhance transparency and accessibility in drug pricing.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
738
CEO
Ms. Wendy Barnes
Country
United States
IPO Year
2020
Website
www.goodrx.comGoodRx Holdings Inc. (GDRX) Latest News & Analysis
Latest News
GoodRx Holdings, Inc. will release Q1 2025 financial results on May 7, 2025, after market close, followed by a conference call on May 8 at 5:00 a.m. PT.
GoodRx's upcoming financial results and conference call provide insights into the company's performance, influencing stock valuation and investor sentiment in the healthcare sector.
GDRX has launched an e-commerce platform linking users to major retail pharmacies to enhance savings, access, and expand digital health services.
GDRX's new e-commerce platform enhances its service offerings, potentially increasing user engagement and revenues, which can positively impact stock performance and market position.
GoodRx has partnered with Hy-Vee to launch an eCommerce platform that allows consumers to check medication availability and purchase online at retail pharmacies.
GoodRx's eCommerce launch with Hy-Vee enhances its service offering, potentially increasing user engagement and revenue, which could positively impact its stock performance.
GoodRx (Nasdaq: GDRX) has launched a new e-commerce experience for retail pharmacies, starting with Hy-Vee, to enhance medication access and inventory validation for consumers.
GoodRx's new e-commerce feature enhances user experience and may increase transaction volume, potentially boosting revenue and market share, signaling growth prospects for investors.
GoodRx is upgraded to a buy, showing strong adjusted EBITDA despite slower growth. The new CEO is shifting strategy to build direct ties with pharmaceutical manufacturers.
GoodRx's stock upgrade and strong adjusted EBITDA signal potential for recovery and private equity interest, while a strategic shift under new leadership may enhance growth prospects.
GoodRx appointed Aaron Crittenden as President of Rx Marketplace and Scott Pope as Chief Pharmacy Officer, effective immediately, to enhance management and financial performance.
Leadership changes can signal strategic shifts that impact company performance. New executives might drive growth or enhance operational efficiency, affecting stock value and investor sentiment.
Frequently Asked Questions About GDRX Stock
What is GoodRx Holdings Inc.'s (GDRX) stock forecast for 2025?
Based on our analysis of 25 Wall Street analysts, GoodRx Holdings Inc. (GDRX) has a median price target of $6.00. The highest price target is $9.00 and the lowest is $4.75.
Is GDRX stock a good investment in 2025?
According to current analyst ratings, GDRX has 8 Buy ratings, 7 Hold ratings, and 1 Sell ratings. The stock is currently trading at $4.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GDRX stock?
Wall Street analysts predict GDRX stock could reach $6.00 in the next 12 months. This represents a 25.0% increase from the current price of $4.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is GoodRx Holdings Inc.'s business model?
The company operates a digital healthcare platform that aggregates pricing data from over 70,000 pharmacies, enabling users to find discounts, coupons, and compare medication prices. GoodRx generates revenue primarily through advertising and referral fees from pharmacies when users redeem prescriptions via its platform.
What is the highest forecasted price for GDRX GoodRx Holdings Inc.?
The highest price target for GDRX is $9.00 from Scott Schoenhaus at Keybanc, which represents a 87.5% increase from the current price of $4.80.
What is the lowest forecasted price for GDRX GoodRx Holdings Inc.?
The lowest price target for GDRX is $4.75 from at , which represents a -1.0% decrease from the current price of $4.80.
What is the overall GDRX consensus from analysts for GoodRx Holdings Inc.?
The overall analyst consensus for GDRX is neutral. Out of 25 Wall Street analysts, 8 rate it as Buy, 7 as Hold, and 1 as Sell, with a median price target of $6.00.
How accurate are GDRX stock price projections?
Stock price projections, including those for GoodRx Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.